Oliver Sartor, MD, of Mayo Clinic, discusses the phase III PSMAfore trial, which analyzed the use of 177Lu-PSMA-617 against an alternative androgen receptor pathway inhibitor – either abiraterone or enzalutamide – in taxane-naive patients with metastatic castration-resistant prostate cancer.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates, and the associated low risk of grade 3-4 adverse events. While he notes that there is still more to learn regarding patient dosing and scheduling, the trial researchers hope to gain an FDA approval for the treatment to benefit patients who may be ineligible for chemotherapy.
(0:00) PSMAfore Study Findings
(5:58) Implications for Future Research
(7:01) Unexpected Trends and Findings
(7:58) Practical Applications of RLT
(9:04) Further Exploration
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.